Results from Hengrui’s completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss, to be presented in an oral session ...

Rani Therapeutics secured a $1.085 billion collaboration with Chugai Pharmaceutical. Check out why I am initiating with a Buy ...

Roche has taken a lead in the oral SERD category of breast cancer therapies with the presentation of new data at ESMO showing ...

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy ...

After four days of intense competition against 82 of the world’s best student teams, the team celebrated winning the Team ...

At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing loca ...

From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing ...

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, Octobe ...

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its ...

PHILADELPHIA, PA — Virion Therapeutics, LLC announced that new clinical data from its VRON-0200 program for chronic Hepatitis ...

Volunteers at three dental clinics on Church-operated high school campuses in Samoa, Tonga and Kiribati are serving the ...